Opinion|Videos|January 9, 2025
Emerging Treatments for Patients with NMIBC
Author(s)Mark D. Tyson II, M.D., M.P.H.
A panelist discusses how emerging investigational agents for NMIBC show promise through diverse mechanisms, including oncolytic viruses (CG0070), immune checkpoint inhibitors (durvalumab, sasanlimab), targeted drug delivery systems (TAR-200), mitomycin-containing gels (UGN-102/103), immunotherapies (TARA-002), gene therapies (EG-70), and FGFR inhibitors (erdafitinib), representing a robust pipeline of potential treatment options.
Advertisement
- Please give an overview and your overall impressions about selected investigational agents to treat patients with NMIBC.
- Cretostimogene grenadenorepvec (CG0070)
- Durvalumab
- Tar-200
- UGN-102 and UGN 103
- Sasanlimab
- TARA-002
Advertisement
Related to this article
The approval is supported by data from the phase 3 VOLGA trial.
enGene expects to initiate a BLA submission by the end of 2026.
Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.
A national survey of US military service members and veterans with NMIBC found that more than half were diagnosed by age 50, while 63% reported treatment access barriers.
VOLGA results raise the question of treatment de-intensification in perioperative MIBC care, according to Suzanne B. Merrill, MD, FACS.
Virtuoso Surgical expects to initiate a focused US launch at leading urology centers in 2027.
The combination of nogapendekin alfa inbakicept plus BCG demonstrated a statistically significant improvement in efficacy vs BCG alone.
Patient goals, disease features, and response to prior therapy guide treatment choices across high-risk NMIBC, according to Suzanne B. Merrill, MD, FACS.
Advertisement
Advertisement
Trending on Urology Times
1
Treatment interruptions in prostate cancer: Balancing PSA kinetics and quality of life
2
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
3
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
4
FDA approves durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC
5